HealthTrust Honors Five Colleagues with CEO Core Value Awards

NASHVILLE, Tenn.–(BUSINESS WIRE)–#accountability—HealthTrust Performance Group™ (HealthTrust), a leading healthcare performance improvement organization, proudly recognized five outstanding employees with its CEO Core Value Awards, which honor colleagues who exemplify the organization’s core values through exceptional performance and peer-nominated excellence. Presented annually by HealthTrust President and CEO, Ed Jones, the CEO Core Value Awards represent the highest … [Read more…]

LGM Pharma Expands U.S. Manufacturing, Bringing Total Investment to $15M Across Texas and Colorado Sites

— $9M Second Phase of CDMO Investment Builds on 2025 $6M Expansion, Funding Facility Upgrades and Increased Capacity for Suppository, Semi-Solid, and Oral Solid Dose Capacity — — Enhancements Strengthen Domestic Supply Chains for Finished Dose Manufacturing, Complementing Extensive API Sourcing and Analytical Testing Services — BOCA RATON, Fla.–(BUSINESS WIRE)–#505b2–LGM Pharma, a leading provider of … [Read more…]

UK-First AI Case-Finding Pathway Launched to Improve Early Detection of Oesophageal and Gastric Cancer

LONDON–(BUSINESS WIRE)–A new NHS-first, AI-enabled case-finding pathway has launched across North East Essex, aiming to improve the early detection of Oesophageal and stomach cancers, some of the hardest cancers to diagnose early and among those with the poorest outcomes in England. Delivered in partnership between AstraZeneca, C the Signs, NHS Suffolk and North East Essex … [Read more…]

Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS

Results supported by key neuroaxonal injury biomarkers pNfH and NfL after six months of treatment AP-101 is an investigational human-derived antibody therapeutic that selectively targets the misfolded, toxic form of SOD1 to disrupt progressive spread of ALS Data featured in oral presentation at the AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases Preparations underway … [Read more…]

Kao’s Bioré Accelerates Global Growth with Entry into the South Korean Market and the Launch of a Unified Global Campaign

TOKYO–(BUSINESS WIRE)–#BioreUV–Kao Corporation (TOKYO:4452) today announced that its skincare brand Bioré will accelerate its international expansion as it enters the South Korean market and rolls out a globally unified campaign. As a core brand under Kao’s “Global Sharp Top” strategy—aimed at establishing leadership in key market segments through high-value products—Bioré plays a central role in … [Read more…]

FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs

Expanded label for once-yearly parasiticide treatment for dogs now includes Haemaphysalis longicornis (Asian longhorned tick) and Amblyomma maculatum (Gulf Coast tick) for 12 months RAHWAY, N.J.–(BUSINESS WIRE)–Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today announced the … [Read more…]

Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss

The Smart Neurostimulation System is the first neurostimulation device to receive Breakthrough designation for TBI-related memory loss; the implant decodes memory states from neural activity on 60 channels spanning four brain regions and delivers AI-guided personalized stimulation therapy to lateral temporal cortex BOSTON–(BUSINESS WIRE)–Nia Therapeutics announced that the U.S. Food and Drug Administration has granted … [Read more…]

QHP Announces $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals

The transaction provides liquidity option to existing investors and secures long-term capital to support continued growth. RALEIGH, N.C.–(BUSINESS WIRE)–On February 13, 2026, QHP Capital, L.P. (“QHP”) announced the closing of a $1.1 Billion single-asset continuation vehicle for Azurity Pharmaceuticals, Inc. (“Azurity”). The transaction provides liquidity to existing limited partners while enabling QHP to maintain control … [Read more…]

Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026

LOS ANGELES–(BUSINESS WIRE)–Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced that its first-in-class approach for treating hair loss with investigational medicine PP405 will be featured in a presentation about advances in the hair loss treatment landscape and regenerative mechanisms on Saturday, March 28th at the American Academy of Dermatology (AAD) Annual Meeting, taking … [Read more…]

Inocras and Broad Institute Researchers Will Release Novel Insights From TCGA Cancer Whole-Genome Analysis at AACR Annual Meeting 2026, Empowering a New Era of Precision Oncology

Comprehensive analysis of one of the largest datasets with harmonized variant calls from over 8,000 cancer whole genomes enables researchers worldwide to uncover rare drivers, new targets, and AI-ready insights that could reshape precision oncology. SAN DIEGO–(BUSINESS WIRE)–#BroadInstitute–Researchers at Inocras, a bioinformatics-led precision health company harnessing the power of whole-genome sequencing (WGS) data and proprietary … [Read more…]